TABLE 4.
Median number of PBMC secreting IFN-γ (SFC/106) in response to influenza virus strains as measured at days 0, 6, and 13 by the ELISPOT assay
| Strain, serostatus,a and treatment | Day 0b
|
Day 6
|
Day 13
|
|||
|---|---|---|---|---|---|---|
| nc | Median SFC/106 PBMC (95% CI) | n | Median SFC/106 PBMC (95% CI) | n | Median SFC/106 PBMC (95% CI) | |
| A/H1N1 | ||||||
| All | ||||||
| CAIV-T 107 | 8 | 1 (1, 10) | 8 | 13 (1, 303) | 5 | 55 (37, 230) |
| CAIV-T <105 | 11 | 1 (1, 1) | 7 | 1 (1, 20) | 11 | 1 (1, 1) |
| TIV | 9 | 1 (1, 3) | 10 | 1 (1, 122) | 9 | 3 (1, 17) |
| Placebo | 8 | 1 (1, 2) | 8 | 1 (1, 23) | 9 | 1 (1, 13 |
| Seronegative | ||||||
| CAIV-T 107 | 6 | 1 (1, 3) | 6 | 8 (1, 303) | 5 | 55 (37. 230) |
| CAIV-T <105 | 9 | 1 (1, 1) | 6 | 1 (1, 1) | 10 | 1 (1, 1) |
| TIV | 5 | 1 (1, 1) | 6 | 1 (1, 1) | 5 | 1 (1, 3) |
| Placebo | 7 | 1 (1, 2) | 5 | 1 (1, 1) | 6 | 1 (1, 1) |
| A/H3N2 | ||||||
| All | ||||||
| CAIV-T 107 | 7 | 1 (1, 17) | 7 | 3 (1, 200) | 5 | 67 (23, 193) |
| CAIV-T <105 | 10 | 1 (1, 1) | 7 | 1 (1, 2) | 9 | 1 (1, 1) |
| TIV | 9 | 1 (1, 3) | 8 | 1 (1, 85) | 6 | 3 (1, 124) |
| Placebo | 7 | 1 (1, 1) | 7 | 1 (1, 1) | 6 | 1 (1, 10) |
| Seronegative | ||||||
| CAIV-T 107 | 6 | 1 (1, 3) | 6 | 2 (1, 30) | 4 | 104 (23, 193) |
| CAIV-T <105 | 10 | 1 (1, 1) | 7 | 1 (1, 2) | 8 | 1 (1, 1) |
| TIV | 5 | 1 (1, 1) | 5 | 1 (1, 3) | 3 | 1 (1, 2) |
| Placebo | 7 | 1 (1, 1) | 7 | 1 (1, 1) | 6 | 1 (1, 10) |
| B | ||||||
| All | ||||||
| CAIV-T 107 | 7 | 1 (1, 2) | 6 | 3 (1, 33) | 5 | 130 (1, 237) |
| CAIV-T <105 | 7 | 1 (1, 3) | 5 | 1 (1, 23) | 5 | 1 (1, 7) |
| TIV | 5 | 1 (1, 10) | 5 | 1 (1, 3) | 5 | 1 (1, 63) |
| Placebo | 5 | 1 (1, 13) | 4 | 1 (1, 1) | 5 | 1 (1, 15) |
| Seronegative | ||||||
| CAIV-T 107 | 4 | 1 (1, 2) | 3 | 3 (1, 33) | 3 | 213 (130, 237) |
| CAIV-T <105 | 3 | 1 (1, 1) | 1 | 1d | 3 | 1 (1, 1) |
| TIV | 4 | 1 (1, 1) | 4 | 1 (1, 3) | 3 | 1 (1, 1) |
| Placebo | 2 | 1 (1, 1) | 2 | 1 (1, 1) | 2 | 1 (1, 1) |
a
Subjects were defined as seronegative to a particular virus strain if their prevaccination HAI antibody titer to that strain was ≤1:4.
b
Prevaccination.
c
n, number of subjects in the calculation.
d
The 95% CI could not be calculated.